gap filled, page-14

Hi Smilez,
Chart wise we look at a correction, which is only healthy at this point.
We had entered overbought territory, in my opinion.
My buy order sits at 6 cents for further accumulation in this great coy.

Regardless wether we see a small or big client signing first, it will not really matter in the medium term.
Wether to grow organically from small to bigger company or to be rerated in one big move will, in all likelihood, see the same outcome as this technology will, in my opinion, be commonplace in bioassays.

The time needed to establish a new technology within lab setups is lengthy as restructuring those is cost extensive. Once technology innovations are offsetting those costs effectively, labs will be restructured in a continuous move.

Consolidation phases are welcomed periods for LT investors to accumulate further.

Regarding speculation surrounding Roche, they just reduced their workforce considerably, discontinued several of their research proprams and are therefore in a cash friendly position to innovate still existing product lines and maintained research programs.